Eupraxia Pharmaceuticals Inc. (OTCMKTS:EPRXF – Get Free Report)’s stock price fell 9.3% on Tuesday . The company traded as low as C$6.67 and last traded at C$6.67. 174,229 shares were traded during mid-day trading, an increase of 2,251% from the average daily volume of 7,410 shares. The stock had previously closed at C$7.36.
Eupraxia Pharmaceuticals Stock Down 9.3%
The firm’s fifty day moving average price is C$6.61 and its 200-day moving average price is C$7.04.
About Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals, Inc (OTCMKTS:EPRXF) is a clinical-stage biotechnology company advancing adeno-associated virus (AAV)-based gene therapies for rare inherited metabolic disorders. The firm’s research platform focuses on developing single-administration treatments designed to address the underlying genetic causes of enzyme deficiencies. Eupraxia’s approach leverages targeted gene delivery to restore or supplement critical metabolic functions in patients with life-threatening conditions.
The company’s lead pipeline candidates include EPRX-101 for Ornithine Transcarbamylase (OTC) deficiency and EPRX-102 for methylmalonic acidemia (MMA), both of which are in preclinical or IND-enabling stages.
Further Reading
- Five stocks we like better than Eupraxia Pharmaceuticals
- Dutch Bros Sell-Off Creates a Growth Opportunity
- NVIDIA’s MediaTek Bet Shows How It Plans to Defend Its AI Moat
- Is Abercrombie & Fitch’s Hot Streak Just Getting Started?
- Medtronic’s Stars Are Aligning for a Price Recovery
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
